SCHEMBL4569306

SCHEMBL4569306

COc1ccc(Cn2cnc3c(N[C@@H](C)c4cc5cccc(Cl)c5c(C(=O)N5CCOCC5)n4)ncnc32)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
PDE10A Q9Y233 2/20 0.40
EGFR P00533 1/20 0.39
NR3C1 P04150 2/20 0.39
YTHDC1 Q96MU7 3/20 0.38
SOS1 Q07889 2/20 0.37
PIK3CB P42338 2/20 0.37
PIK3CD O00329 1/20 0.37
PIK3R2 O00459 1/20 0.37
PIK3CA P42336 1/20 0.37
PIK3CG P48736 1/20 0.37
PIK3R5 Q8WYR1 1/20 0.37
PIK3R3 Q92569 1/20 0.37
DGAT1 O75907 1/20 0.37
HPGD P15428 2/20 0.36
FGFR1 P11362 2/20 0.36
FGFR4 P22455 2/20 0.36
RAB9A P51151 2/20 0.36
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3699662 0.90 HDAC1 (0.42) HDAC1HDAC6PDE10ANR3C1YTHDC1
SCHEMBL3699660 0.90 HDAC1 (0.42) HDAC1HDAC6PDE10ANR3C1YTHDC1
SCHEMBL4569444 0.89 HDAC1 (0.43) HDAC1HDAC6PDE10AEGFRNR3C1
SCHEMBL3706244 0.88 HDAC1 (0.47) HDAC1HDAC6NR3C1YTHDC1HPGD
SCHEMBL3695038 0.88 HDAC1 (0.47) HDAC1HDAC6NR3C1YTHDC1HPGD
SCHEMBL3695037 0.88 HDAC1 (0.47) HDAC1HDAC6NR3C1YTHDC1HPGD
SCHEMBL3706237 0.88 HDAC1 (0.47) HDAC1HDAC6NR3C1YTHDC1HPGD
SCHEMBL3699064 0.86 PDE10A (0.41) HDAC1HDAC6PDE10AEGFRYTHDC1
SCHEMBL3699067 0.86 PDE10A (0.41) HDAC1HDAC6PDE10AEGFRYTHDC1
SCHEMBL17913948 0.85 SOS1 (0.44) EGFRSOS1PIK3CDPIK3R2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9388183-B2 Heterocyclic compounds and uses thereof INFINITY PHARMACEUTICALS, INC. (US) 2016-07-12 US disclosed
US-20150031672-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF INFINITY PHARMACEUTICALS, INC. 2015-01-29 US disclosed
US-8901133-B2 Heterocyclic compounds and uses thereof INFINITY PHARMACEUTICALS, INC. (US) 2014-12-02 US disclosed
US-20120122838-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF INFINITY PHARMACEUTICALS, INC. 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150031672-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF PIK3CA, PIK3CD, PIK3CB HDAC1 440/4885HDAC6 340/4885PDE10A 455/4885
US-20120122838-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF PIK3CA, PIK3CD, PIK3CB HDAC1 440/4885HDAC6 340/4885PDE10A 455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.